[go: up one dir, main page]

WO2017168454A3 - Novel compounds as btk inhibitors - Google Patents

Novel compounds as btk inhibitors Download PDF

Info

Publication number
WO2017168454A3
WO2017168454A3 PCT/IN2017/050127 IN2017050127W WO2017168454A3 WO 2017168454 A3 WO2017168454 A3 WO 2017168454A3 IN 2017050127 W IN2017050127 W IN 2017050127W WO 2017168454 A3 WO2017168454 A3 WO 2017168454A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
btk inhibitors
preparation
tyrosine kinase
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2017/050127
Other languages
French (fr)
Other versions
WO2017168454A2 (en
Inventor
Prabal Sengupta
V.S.N. Murty KADIYALA
Dipali Manubhai DESAI
Sabbirhusen Yusufbhai CHIMANWALA
Tushar Mukund JARAG
Gaurav Sanjivkumar Sheth
Trinadha Rao Chitturi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of WO2017168454A2 publication Critical patent/WO2017168454A2/en
Anticipated expiration legal-status Critical
Publication of WO2017168454A3 publication Critical patent/WO2017168454A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel compounds of Formula I as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.
PCT/IN2017/050127 2016-04-02 2017-04-03 Novel compounds as btk inhibitors Ceased WO2017168454A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621011745 2016-04-02
IN201621011745 2016-04-02
IN201621023892 2016-07-12
IN201621023892 2016-07-12

Publications (2)

Publication Number Publication Date
WO2017168454A2 WO2017168454A2 (en) 2017-10-05
WO2017168454A3 true WO2017168454A3 (en) 2018-10-11

Family

ID=59962693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050127 Ceased WO2017168454A2 (en) 2016-04-02 2017-04-03 Novel compounds as btk inhibitors

Country Status (1)

Country Link
WO (1) WO2017168454A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10479786B2 (en) * 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
KR20220054066A (en) * 2020-10-23 2022-05-02 (주)메디톡스 Protein kinase inhibitor and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009226A1 (en) * 2009-07-22 2011-01-27 北京莱博赛路森药物科技有限公司 Preparation method of dasatinib derivatives useful as antitumor agents and their intermediates
EP2308833A2 (en) * 1999-04-15 2011-04-13 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308833A2 (en) * 1999-04-15 2011-04-13 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2011009226A1 (en) * 2009-07-22 2011-01-27 北京莱博赛路森药物科技有限公司 Preparation method of dasatinib derivatives useful as antitumor agents and their intermediates

Also Published As

Publication number Publication date
WO2017168454A2 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
WO2015039612A8 (en) Compound inhibiting activities of btk and/or jak3 kinases
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
MX2021004431A (en) Novel processes.
SA515360007B1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors
WO2016172134A3 (en) Novel compounds
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
HK1252378A1 (en) Tyrosine kinase inhibitors
WO2016109217A3 (en) Btk inhibitors
WO2015101957A3 (en) Inhibitors of glutaminase
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
EP4338802A3 (en) Tyk2 inhibitors, uses, and methods for production thereof
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
TN2017000158A1 (en) Carbazole derivatives
PH12015502365A1 (en) Bace1 inhibitors
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
MY201535A (en) Therapeutic compounds
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
CA3007110C (en) Heterocycle compounds and uses thereof
WO2017168454A3 (en) Novel compounds as btk inhibitors
MX2017014752A (en) Novel amidoheteroaryl aroyl hydrazide ethynes.
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
PH12017501668A1 (en) Bace1 inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17773458

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17773458

Country of ref document: EP

Kind code of ref document: A2